Cancer immunotherapy is an innovative treatment method that enhances the body's immune system to combat and regulate cancer. Dr Pouya Faridi uses leading-edge technologies to find new targets for advancing cancer immunotherapy.
Areas of interest
A specialist in the fields of tumour immunology and mass spectrometry techniques, Dr Pouya Faridi’s goal is to discover innovative targets that can drive the development of cutting-edge precision immunotherapies for the next generation of medicine. His research focus is on creating advanced multi-omics techniques, including immunopeptidomics, proteomics, transcriptomics, and genomics.
Dr Faridi is a Group Head at Hudson Institute and Senior Research Fellow, Department of Medicine, Monash University.
Dr Faridi has made notable contributions to the field of immunopeptidomics and antigen discovery, including the development of methods for identifying non-canonical antigens and pioneering techniques for translating immunopeptidomics findings into practical applications. His research breakthroughs in non-canonical antigens, specifically proteasomal spliced peptides, have paved the way for the pioneering ‘first in human’ study involving a spliced peptides vaccine for cancer patients.
Dr Pouya Faridi has secured over $6 million in grant and fellowship funding from diverse sources including international, national, and state government agencies (such as DoD US, NHMRC, Cancer Australia, and Victorian Cancer Agency), as well as from philanthropic organisations including the Isabella and Marcus Foundation, Australian Lions Childhood Cancer Research Foundation, and My Room Children’s Cancer Charity.